ORIC Pharmaceuticals Partners With Cancer Research UK on ORIC-259
ORIC Pharmaceuticals announced a partnership with Cancer Research UK to advance ORIC-259. Cancer Research UK will fund and execute studies and Phase 1/2 trials for the drug. ORIC retains an option to reacquire rights after Phase 1/2 data, with Cancer Research UK eligible for milestones and royalties.